Health breakthroughs and money matters, in plain words

Home » FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer

FDA Denies Approval for Summit Therapeutics’ Ivonescimab in Lung Cancer

By

–

FDA Denies Approval for Summit Therapeutics' Ivonescimab in Lung Cancer

The Food and Drug Administration has denied approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.

The FDA issued a complete response letter for Summit’s biologics license application, stating the company has not established evidence of effectiveness because the therapy did not show a statistically significant overall survival benefit. The agency argued that the drug’s progression-free survival benefit, while real, is not enough on its own to indicate a positive benefit-risk profile for approval.

A Setback for Patients and Families

For families and patients in the United States awaiting new options for this specific form of lung cancer, the news is a significant disappointment. The decision comes despite ivonescimab showing it could slow the progression of the cancer in a major clinical trial.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Robert Duggan, Co-CEO of Summit, in a Sunday statement. He framed the company’s pursuit of approval as a mission to provide help to those in need, based on evidence from a global study he believed showed a treatment option these patients required.

The Data Behind the Decision

Summit had submitted its application with evidence from the Phase 3 HARMONi trial. That trial demonstrated improved progression-free survival for patients taking ivonescimab in combination with chemotherapy compared to a placebo. This outcome suggested that the therapy could successfully extend the time before a patient’s cancer worsened, a meaningful goal for many.

However, the trial’s results were mixed when it came to the most critical measure: overall survival. While the drug showed a positive trend, it did not achieve the statistically significant improvement in how long patients lived that the FDA requires for approval. In September, Summit presented additional data from a longer follow-up that showed a slight benefit on overall survival across the global population, including both Asian and Western patients. Analysts had been optimistic that this new information would be enough to secure the FDA’s green light, but it was not.

A Global Treatment, a U.S. Hurdle

The rejection marks a difficult regulatory hurdle for Summit, even as ivonescimab has already found a home for patients elsewhere. The drug has been available in China through Summit’s partner, Akeso, since 2024 for this same indication. This international availability highlights the different paths a treatment can take, offering hope to some patients while facing a roadblock in others.

Analysts had high hopes for ivonescimab, which is a PD-1xVEGF bispecific antibody. Some had even referred to it as a potential “Keytruda killer” after it outperformed Merck’s blockbuster cancer drug in a head-to-head trial in China. The overall market for this class of drugs is projected to reach $30 billion by 2032, with specific forecasts for ivonescimab reaching $4.4 billion for several indications by 2030.

Summit pledged to continue developing the therapy for multiple types of cancer, including several forms of non-small cell lung cancer. The company has not yet outlined its next specific steps for the EGFR-mutated indication in the U.S. following this setback. For now, the path forward for this promising treatment in the American market remains uncertain. Talk to your doctor or oncologist.

Sources

Photo: The U.S. Food and Drug Administration (Public domain)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News